OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp8

• Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthrit…

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

Wonderful Philip Hench Memorial Lecture from Prof Gerd Bursmester on the development of biologics in rheumatology from infections, the magic bullet, serendipity, perseverance, research to the present day @RheumNow #ACR20 #3S007 https://t.co/9H1AmZLTpJ

ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s

Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk

CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC

• Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis D…

In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX

Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug. #RheumTwitter #lupus Abs#0849 #ACR20 @RheumNow https://t.co/8a6OcZmOso

• Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrate…

The development of biologics started with diphtheria- history of Medicine! Look how far we have come now prescribing over 50 different types of biologics! @RheumNow #acr20 https://t.co/XbygK5g7ON

Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs

Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj

Great job by @Rheumnow's Dr. Jonathan Kay on CT-P17, ADA biosimilar in Abst#0800. Similar ACR20 83% rate for ADA and CT-P17 with similar safety profile. #ACR20.

What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20

Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20

Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7